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Abstract 
Purpose: To assess the clinical efficacy and side effects of radiotherapy combined with sodium 
glycididazole in the treatment of recurrent esophageal carcinoma. 
Methods: Ninety patients with locally recurrent oesophageal carcinoma who were admitted to the 
Oncology Department at Taian City Central Hospital, Shandong, China, were randomly divided into a 
treatment group (treated with radiotherapy and sodium glycididazole) and a control group (treated with 
radiotherapy alone) in a randomized study. Short-term curative effects, median progression-free survival 
(PFS), and side effects were compared between the two groups. 
Results: The cure rate in the treatment group was 86.70 %, whereas that in the control group was 
51.10 % (p < 0.05). Median PFS in the treatment group was 9.9 months versus 5.3 months in the 
control group (p < 0.05). Side effects in both groups included alopecia, headache, nausea, vomiting and 
leucopaenia, at level one or two. In this regard, the difference between the two groups was statistically 
insignificant (p > 0.05). 
Conclusion: Radiotherapy combined with sodium glycididazole shows a higher short-term curative 
effect in the treatment of recurrent oesophageal carcinoma than radiotherapy alone.  
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Oesophageal carcinoma is a common 
gastrointestinal tract cancer and has high 
morbidity and mortality among malignant cancers 
[1,2]. Today, surgery is the major treatment 
method for oesophageal cancer [3,4]. However, 
the anatomical structure of the oesophagus 
causes skip metastasis in lymph nodes, making 
the elimination of lymph nodes during surgery 
more difficult. Thus, operative treatment alone 
does not control recurrence and metastasis of 
the disease and typically results in unsatisfactory 
long-term effects. Postoperative local recurrence 
and distant metastasis contribute to this failure of 
surgical treatment [5,6]. 
 
More than 40 % of patients are likely to have 
mediastinal lymph node metastasis or 
anastomotic recurrence after undergoing radical 
resection for oesophageal carcinoma, but it is 
often difficult for recurrent patients to undergo 
further surgery; thus, radiotherapy becomes the 
main treatment method [7]. However, 
radiotherapeutic effects are less than ideal. One 
of the main factors influencing radiotherapeutic 
efficacy is the insensitivity of 10 – 50 % of 
hypoxic cells in a solid carcinoma to low linear 
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energy transfer (LET) rays [8]. It has been shown 
clinically that many chemotherapy drugs can 
increase sensitivity; however, there are some 
adverse effects [9]. Sodium glycididazole, the 
only formally clinically used radiosensitiser with 
high efficacy and low toxicity, is a safe and 
effective radiosensitiser for hypoxic cells. In this 
study, we treated recurrent oesophageal cancer 
using radiotherapy combined with sodium 





Ninety patients with confirmed recurrent 
oesophageal carcinoma, who were admitted to 
the Oncology Department at Taian City Central 
Hospital, Shandong, China from May 2013 to 
May 2015 were enrolled. Out of the number, 
there were 54 men and 36 women (age range, 
39 – 79 years, mean age, 56.7 ± 2.3 years). 
Karnofsky performance status scores of the 
patients were all > 70 points; the diameter of the 
tumour was from 1.8 – 6.1 cm and the average 
tumour volume was 88 cm2. The regional lymph 
nodes metastasis rate was 74.40 %, among 
which cervical lymph node metastasis accounted 
for 16.70 %, mediastinal lymph node metastasis 
for 25.60 %, cervical lymph node metastasis and 
mediastinal lymph node metastasis for 22.20 %, 
and anastomotic recurrence for 7.80 %. Patients 
were divided randomly into a treatment group (45 
patients treated with radiotherapy and sodium 
glycididazole) and a control group (45 patients 
treated with radiotherapy alone). 
 
This study was approved by the Medical Ethics 
Committee of Taian City Central Hospital 
(approval no. TCCH20151004JYY) and followed 
the guidelines of the Declaration of Helsinki [10]. 




Three-dimensional intensity modulated radiation 
therapy and 6-MV X-ray conventional 
segmentation treatment were used. Patients 
were given 1.8 – 2 Gy each time, five times per 
week. The total radiation to the gross tumour 
volume was 60 – 66 Gy, while that to the clinical 
target volume was 50 – 50.4 Gy. 
 
Sodium glycididazole was provided by Shandong 
Green Pharmaceutical Co., Ltd., China. Sodium 
glycididazole for injection (800 mg/m2) was 
dissolved and diluted with 100 mL normal saline. 
Patients were given an intravenous infusion over 
30 min. Patients then received conventional 
radiotherapy within 120 min. This process was 
repeated three times per week until the end of 
radiotherapy. 
 
Patients in the treatment group were treated with 
radiotherapy and sodium glycididazole; those in 
the control group were treated with radiotherapy 
alone. 
 
Evaluation of clinical and side effects 
 
In evaluating the response to radiotherapy, we 
used the Response Evaluation Criteria in Solid 
Tumours (World Health Organization) [11]. 
Complete remission (CR) referred to the 
disappearance of all target tumours. Partial 
remission (PR) meant that the size of target 
tumours was reduced by 30 %. Stable disease 
(SD) meant that the reduction in the size of the 
target tumours did not reach the standard for 
partial remission and the increase did not reach 
the standard for progression. Progressive 
disease (PD) meant that the size of the target 
tumours increased by 20 % or there were new 
lesions. The formula for the overall effective rate 
was: overall effective rate = (number of cases of 
complete remission + number of cases of partial 
remission) / total number of cases.  
 
Adverse reactions were divided into four levels 
according to the National Cancer Institute 
Common Terminology Criteria for Adverse 
Events (ver. 3.0; NCI-CTC). Progression-free 
survival (PFS) was defined as the period from 





Data were analysed using SPSS software (ver. 
20.0, IBM, Armonk, NY, USA) and further 
assessed using χ2 tests. The data are expressed 
as percentages (%). Comparison of data 
between the two groups was made using t-tests. 
The data are expressed as mean ± standard 
deviation (SD). For survival analysis, we used 
Kaplan–Meier method. P < 0.05 were taken to 






Complete remission rates in the treatment and 
control groups were 26.70 % and 17.80 %, 
respectively (χ2 = 1.157, p > 0.05). There was no 
significant difference between the groups. 
Overall response rates (CR + PR) were 88.90 % 
and 51.10 % respectively; there was a significant 
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difference between groups (χ2 = 5.03, p < 0.05). 
Specific results are provided in Table 1. 
 
Analysis of survival rate 
 
The median PFS in the treatment group was 9.9 
months (95 % confidence interval (CI) = 5.13 – 
14.67 months), whereas that of the control group 
was 5.3 months (95 % CI = 3.16 – 7.48 months); 
the difference was statistically significant (p < 
0.05; Figure 1). 
 
Side effects in both two groups included 
alopecia, headache, nausea, vomiting, and 
leucopaenia. The difference between the two 
groups was statistically insignificant (p > 0.05). 
Alopecia was at level two, and the other 
reactions were at level one (Table 2). There was 
no level three or four side effect. No serious 






Anastomotic recurrence and/or mediastinal 
lymph node metastasis are the major reasons 
why patients who undergo oesophageal 
carcinoma operations die after 2 – 3 years. By 
analysing 175 patients with recurrent 
oesophageal carcinoma who underwent three-
field operations, Li et al [12] found that the 
lymphatic metastasis rate was 90.29 %, the 
anastomotic recurrence rate was 19.43 %, and 
the tumour area recurrence rate was 9.71 %. 
Among lymph node metastases, mediastinal 
lymph node metastasis at the superior 
mediastinum was the most commonly seen; 
abdominal lymph node metastasis is common 
with lower thoracic oesophageal carcinomas.  
 
Zhu et al [13] analysed recurrence 
retrospectively in 98 cases of oesophageal 
carcinoma and found that lymph node metastasis 
ranked first, anastomotic recurrence second, and 
tumour area recurrence was the least common.  
Table 1: Short-term effects of radiotherapy for recurrent oesophageal carcinoma [N (%)] 
 
Group CR PR SD PD ORR (%) 
Treatment group (N=45) 12(26.70) 28(62.20) 3(6.70) 2(4.40) 88.90 
Control group (N=45) 8(17.80) 15(33.30) 14(31.10) 8(17.80) 51.10 




Figure 1: Analysis of progression-free survival (PFS) curves 
 
     Table 2: Comparison of toxic and side effects between the groups 
 
Side effect 
Treatment group Control group 
Level 




1 Level 2 Level 3 Level 4 
Alopecia 0 45 0 0 0 45 0 0 
Headache 20 8 0 0 20 9 0 0 
Nausea and vomiting 14 8 0 0 16 9 0 0 
Leucopaenia 11 0 0 0 11 2 0 0 
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Regarding treatment modalities for patients with 
recurrent oesophageal carcinoma, radiotherapy 
is the main method, but its clinical effects are 
unsatisfactory, which is considered to be related 
to hypoxia in cancer cells. Hypoxia, a common 
phenomenon in solid tumours, weakens 
radiotherapeutic efficacy by decreasing 
apoptosis [14]. Sodium glycididazole is a new 
nitroimidazole compound that increases the 
sensitivity to radiation. The drug has no anti-
cancer effect per se; however, it can increase the 
sensitivity of hypoxic cells to radiotherapy and 
chemotherapy. The sensitivity mechanism of 
sodium glycididazole involves (1) strong damage 
and electron fixation and (2) suppression of DNA 
repair enzymes to tumour cells. Specifically, 
ionising radiation damages the tumour cells. The 
electrophilic group of sodium glycididazole 
captures electrons from damaged tumour target 
molecules. This promotes the generation of 
radical cations, accelerating the death of tumour 
cells. The suppression of DNA repair enzymes in 
tumour cells, especially polymerase B, 
strengthens the killing function in tumour cells by 
stopping DNA replication. This, in turn, 
decreases the oxygen dependence during the 
killing of tumour cells, suppressing potentially 
lethal and sub-lethal damage repair. 
 
While sodium glycididazole can increase the 
sensitivity of tumour cells to radiotherapy and 
chemotherapy, it does not affect normal cells 
[15]. Additionally, it is characterised by high 
safety and efficacy because it does not 
accumulate in the patient’s body. Previous 
clinical studies have shown that the drug can 
greatly increase the sensitivity of cells in head 
and neck neoplasms and oesophageal 
carcinoma, and it has good short-term effects 
[16-19]. 
 
A previous study compared the clinical effects of 
radiotherapy combined with sodium glycididazole 
and radiotherapy alone in the treatment of 
patients with brain metastases from breast 
carcinomas. The response rates in the treatment 
and control groups were 88.90 % and 51.10 %, 
respectively; the difference was significant. The 
median PFSs of the two groups were 9.9 and 5.3 
months, respectively; the difference was 
statistically significant.  
 
Our results showed that treating patients with 
recurrent oesophageal carcinoma with 
radiotherapy and sodium glycididazole had 
positive effects, which were better than those in 
the control group. Moreover, we found no 
significant difference between the two groups in 
terms of side effects, such as alopecia, 
headache, nausea, vomiting, and bone marrow 
suppression (p > 0.05). All patients could tolerate 
the side effects; none of the patients 
discontinued treatment, suggesting that sodium 
glycididazole did not aggravate any adverse 
reaction. 
 
Limitations of the study 
 
The sample size in the study was small; thus, 
prospective clinical studies with larger sample 
sizes are required. Also, although there was an 
obvious difference in median PFS between the 
two groups, the research period was only 4 
years. We were unable to show whether there 
was also a difference in longer-term PFS. Thus, 





Sodium glycididazole in combination with 
radiotherapy was more effective clinically in 
treating patients with local oesophageal 
carcinoma recurrence than radiotherapy alone. 
Moreover, the combined therapy did not 
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